A model for treatment strategy in the chemotherapy of aids

Bulletin of Mathematical Biology

Volumn 58, Issue 2, 1996, Pages 367-390

  Kirschner, Denise ^a,b   Webb, G F ^c  

^a TEXAS A AND M UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIOLOGICAL MODEL; COMPARATIVE STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MATHEMATICS; THEORETICAL MODEL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIVIRAL AGENTS; HIV INFECTIONS; HUMANS; MATHEMATICS; MODELS, IMMUNOLOGICAL; MODELS, THEORETICAL; ZIDOVUDINE;

EID: 0030095028     PISSN: 00928240     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02458312     Document Type: Article

References (40)

1. Agur, Z. 1989. A new method for reducing cytotoxicity of the anti-AIDS drug AZT. In Biomedical Modeling and Simulation, D. S. Levine, (Ed), pp. 59-61. J. C. Baltzer AG, Scientific Publishing.
2. Anderson, D. J., et al. 1992. Effects of disease stage and AZT therapy on the detection of HIV-1 in semen. J. Amer. Med. Assoc. 267, 2769-2774.
3. Chow, Y. K., et al. 1993. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361, 650-655.
4. Cojocaru, L. and Z. Agur. 1992. A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Math. Biosci. 109, 85-97.
5. Cojocaru, L. and Z. Agur. 1993. New mathematical methods for evaluating toxicity of anti-cancer drugs and AZT. Preprint.
6. Concorde Coordinating Committee. 1994. MRC/ANRS randomized double-blind controlled trial of immediate and deferred AZT in symptom-free HIV infection. Lancet 343, 871-81.
7. Cooper, D. A., et al. 1991. The efficacy and safety of AZT with or without acyclovir in the treatment of patients with AIDS related complex. AIDS 5, 933-943.
8. Cox, H. P., et al. 1990. Outcomes of treatment with AZT of patients with AIDS and symptomatic HIV infection. Nurse Practitioner 15, 36-43.
9. Dimitrov, D. S. et al. 1993. Quantitation of HIV-type 1 infection kinetics. J. Virology 67, 2182-2190.
10. Fischl, M. A., et al. 1990. The safety and efficacy of AZT in the treatment of subjects with mildly symptomatic HIV type 1. Ann. Int. Med. 112, 727-737.
11. Graham, N. M. H., et al. 1992. The effects on survival of early treatment of HIV infection. New Engl. J. Med. 326, 1037-1042.
12. Hamilton, J. D., et al. 1992. A controlled trial of early vs. late treatment with AZT in symptomatic HIV infection. New Engl. J. Med. 326, 437-443.
13. Harnevo, L. E. 1993. Simple models for interactions of the HIV and the immune system: can we point to a specific threshold for the onset of AIDS? In Proceedings of the World Congress for Non-linear Analysts. To appear.
14. Haseltine, W. A. and F. Wong-Staal. 1988. The molecular biology of the AIDS virus. Scientific American October, 53-62.
15. Hirsch, M. S. 1990. Chemotherapy of HIV infections: Current practice and future prospects. J. Infectious Diseases 161, 845-857.
16. Ho, D. D., et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
17. Kaiser, J. D. 1993. Immune Power. New York: St. Martin's Press.
18. Kirschner, D., R. Mehr and A. Perelson. 1995. The role of the thymus in HIV infection. Preprint.
19. Kirschner, D. and A. Perelson. 1995. A model for the immune system response to HIV: AZT treatment studies. In Mathematical Populations Dynamics III. Theory of Epidemics, O. Arino, D. Axelrod and M. Kimmel (Eds), Vol. 1, pp. 295-310. Winnepeg, Manitoba: Wuerz Publishing.
20. Kirschner, D. E. and G. F. Webb, 1995. Effects of drug resistance on chemotherapy strategies in the treatment of HIV infection. Preprint.
21. Lagakos, S., C. Pettinelli, D. Stein and P. A. Volderding. 1993. The Concorde Trial. Lancet 341, 1276.
22. Landonio, G., et al. 1993. Comparison of two dose regimes of AZT in an open, randomized, muticetre study for severe HIV-related thromocytopenia. AIDS 7, 209-212.
23. Lenderking, W. R., et al. 1994. Evaluation of the quality of life associated with Zidovudine treatment in asymptomatic human immunodeficiency virus infection. New. Engl. J. Med. 330, 738-743.
24. Lundgren, J. D., et al. 1994. Comparison of long-term prognosis of patients with AIDS treated and not treated with Zidovudine. J. Amer. Med. Assoc. 271, 1088-1092.
25. McKallip, R. J., M. Nagarkatti and P. S. Nagarkatti. 1995. Immunotoxicity of AZT: inhibitory effect on thymocyte differentiation and peripheral T cell response to gp120 of HIV. Tox. Appl. Pharm. 131, 53-63.
26. McLean, A. and M. Nowak, 1991. Interactions between HIV and other pathogens. J. Theoret. Biol. 155, 69-86.
27. McLean, A. and M. Nowak. 1992. Competition between AZT sensitive and AZT resistant strains of HIV. AIDS 6, 71-79.
28. McLeod, G. X. and S. M. Hammer. 1992. Zidovudine: 5 years later. Ann. Int. Med. 117, 487-501.
29. Meng, T. C., et al. 1992. Combination therapy with AZT and DDC in patients with advanced HIV infection. Ann. Int. Med. 116, 13-19.
30. Montaner, J., et al. 1993. Clinical correlates of in vitro HIV-1 resistance to AZT. AIDS 7, 189-196.
31. Mulder, J. W., et al. 1994. AZT twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. AIDS 8, 313-321.
32. Nozyce, M., et al. 1994. A 12-month study of the effects of oral AZT on neurodevelopmental functioning in a cohort of vertically HIV-infected inner-city children. AIDS 8, 635-639.
33. Perelson, A. S. 1989. Modeling the interaction of the immune system with HIV. In Mathematical and Statistical Approaches to AIDS Epidermiology. Lecture Notes in Biomath., C. Castillo-Chavez (Ed), Vol. 83, pp. 350-370. New York: Springer-Vrlag.
34. + T cells. Math. Biosci. 114, 81-125.
35. Redfield, R. and D. Burke. 1988. HIV infection: The clinical picture. Scientific American October, 90-98.
36. Ruedy, J., M. Schechter and J. S. G. Montaner. 1990. Zidovudine for early HIV infection: who, when and how? Ann. Int. Med. 112, 721-722.
37. Volberding, P. A. 1994. Intermittent therapy. AIDS 7, 454-456.
38. Volberding, P. A., et al. 1990. Zidovudine in asymptomatic human immunodeficiency virus infection. New. Engl. J. Med. 322, 941-949.
39. Volderding, P. A., et al. 1994. The duration of Zidovudine benefit in persons with asymptomatic HIV infection. J. Amer. Med. Assoc. 272, 437-442.
40. Wolfram, S. A. 1988. Mathematica: A System for Doing Mathematics by Computer. Reading, MA: Addison-Wesley.